Non-small cell lung cancer stage IV

• An Open-label, Multicenter, Phase 1a/1b Study to Evaluate the Safety and Anti-tumor Activity of TT125-802 in Combination With Adagrasib, Osi … Pending
  2024-519071-25-00 3 "Advanced NSCLC"
• Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending
  2025-522790-10-00 4 "Non Small Cell Lung Cancer"
• Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting
  2024-516790-78-00 4 2025-09-04 "stage IV NSCLC (non-small-cell lung cancer)"
• A clinical study of treatments for non-small cell lung cancer (MK-3475-01I) Recruiting
  2024-518839-11-00 4 2025-08-25 "Stage IV Squamous Non-Small Cell Lung Cancer"
• A Multicenter, Open-Label, Dose-Finding, Phase 2 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) in Subjects with Advanced Non-Sm … Recruiting
  2023-504595-26-00 4 2023-05-22 "Non-Small Cell Lung Cancer"
• A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad … Recruiting
  2024-520238-31-01 9 2026-04-20 "Advanced Lung Cancer"
• A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with … Recruiting
  2024-519344-32-00 9 2026-03-16 "Non-small Cell Lung Cancer"
• A Multicenter, Open-label, Randomized Phase 3 Study Evaluating THIO Sequenced with Cemiplimab (LIBTAYO®) vs Investigator Choice of Single-ag … Recruiting
  2024-520164-33-00 5 2025-12-09 "Non-Small Cell Lung Cancer"
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 "Common EGFR-Mutated Locally Advanced or Metastatic Non-Small"
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 "Non-small cell lung cancer"
• A Phase 1 Study Evaluating the Safety, Tolerability, and Efficacy of BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lun … Recruiting
  2023-506539-14-00 3 2025-05-27 "Oncology"
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 "Advanced or Metastatic Non-Squamous NSCLC"
• First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting
  2023-507937-14-00 7 2025-03-25 "Metastatic Solid Tumor"
• A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based c … Recruiting
  2023-506714-43-00 4 2024-03-15 "ALK positive Non-Small Cell Lung Cancer"
• Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Recruitment ended
  2025-521115-40-00 4 2025-09-30 "Advanced or Metastatic Non-small Cell Lung Cancer"
• IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre … Recruitment ended
  2022-502103-30-00 4 2023-04-25 "advanced non-squamous non-small cell lung cancer"
• IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot … Recruitment ended
  2023-510387-13-00 4 2022-05-18 "advanced ALK-positive non-small cell lung cancer"
• Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Recruitment ended
  2022-503028-29-01 4 2021-12-14 "Patients with stage IV EGFR-mutation positive NSCLC target p"
• Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Recruitment ended
  2023-508308-40-00 5 2021-07-30 "Metastatic (stage IV) squamous or nonsquamous non-small cell"
• Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Recruitment ended
  2024-512028-12-00 4 2021-03-19 "Advanced ROS1-positive non-small cell lung cancer"
• Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Recruitment ended
  2024-515944-22-00 4 2021-01-19 "BRAFV600E-mutant metastatic Non-small Cell Lung Cancer"
• An open label, multicenter extension study in patients previously enrolled in a Genentch and/or F. Hoffmann-La Roche Ltd sponsored atezolizu … Recruitment ended
  2023-506184-34-00 5 2019-08-09 "Advanced Malignancies"
• Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors Recruitment ended
  2023-503812-34-00 4 2019-02-13 "Locally Advanced or Metastatic Disease in Solid Tumors"
• A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Adv … Recruitment ended
  2024-516477-73-00 3 2018-03-07 "Bladder cancer and kidney cancer"

Showing 1–24 of 41 trials